BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36499073)

  • 1. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
    Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
    J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
    He L; Du ZD; Wang Y; Meng RQ; Zhao WW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
    Santana-Rivera Y; Rabelo-Fernández RJ; Quiñones-Díaz BI; Grafals-Ruíz N; Santiago-Sánchez G; Lozada-Delgado EL; Echevarría-Vargas IM; Apiz J; Soto D; Rosado A; Meléndez L; Valiyeva F; Vivas-Mejía PE
    Am J Transl Res; 2020; 12(4):1275-1292. PubMed ID: 32355541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
    Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
    Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TR3 modulates platinum resistance in ovarian cancer.
    Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
    Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.
    Fu L; Zhang D; Yi N; Cao Y; Wei Y; Wang W; Li L
    Hum Cell; 2022 Sep; 35(5):1560-1576. PubMed ID: 35907138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
    Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
    Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.
    Li X; Gu F; Niu C; Wang Y; Liu Z; Li N; Pan B; He D; Kong J; Zhang S; Wang X; Yao Y; Zheng L
    J Transl Med; 2015 May; 13():164. PubMed ID: 25990504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L; Zhang B; Li W
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
    He X; Ee PL; Coon JS; Beck WT
    Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Wan J; Shi F; Xu Z; Zhao M
    Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
    Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
    J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.